Analysis of survival from birth of 30 patients with both RA and DB.

<p>RA: rheumatoid arthritis; DB: diffuse bronchiectasis.</p><p>Early-onset DB: respiratory symptoms preceding RA by >10 years (mostly childhood DB).</p><p><i>CFTR</i>: cystic fibrosis transmembrane conductance regulator gene.</p><p>A mixed effect Cox model was used, with shared random effects, depending on the kinship coefficient of individuals.</p><p>The variance of the random effect was 4×10⁻⁴.</p><p>Analysis of survival from birth of 30 patients with both RA and DB.</p

Kaplan-Meier probability of survival from inclusion of the various participants in the study cohort, according to their phenotype.

<p><b>Panel A.</b> Kaplan-Meier survival curves from inclusion in the study for the various groups of individuals. <b>Panel B.</b> Hazard ratios (95% CI) of death after inclusion for the various disease groups, compared with unaffected relatives as the reference group. A mixed effect Cox model was fitted, taking inclusion as the starting point and adjusting for age at inclusion. Individual random effects were assumed to be correlated as a function of the corresponding kinship coefficients. The variance of the random effect was 1.48. RA: rheumatoid arthritis; DB: diffuse bronchiectasis.</p

Kaplan-Meier probability of survival from birth of patients with both RA and DB according to risk of death categories.

<p>The analysis classified RA patients with DB into categories of low or high risk of death. Patients with early onset of DB and CF/<i>CFTR</i>-related disorders mutations were classified in the high group as compared with the other patients with both RA and DB who were classified into the low risk. RA: rheumatoid arthritis; DB: diffuse bronchiectasis. Early-onset DB: respiratory symptoms preceding RA by >10 years (mostly childhood DB). Late-onset DB: respiratory symptoms occurring at the same time or <10 years before RA onset (adulthood DB). Mutations: cystic fibrosis (CF) and cystic fibrosis transmembrane conductance regulator (<i>CFTR</i>)-related disorder mutations. See Patients and Methods for additional information.</p

Kaplan-Meier probability of survival after RA diagnosis in patients, as a function of the presence or absence of associated DB.

<p><b>Panel A</b>. Kaplan-Meier curves of survival after RA diagnosis, as a function of the presence or absence of associated DB. <b>Panel B</b>. Hazard ratios (95% CI) for death after RA diagnosis associated with the presence of DB. A mixed effect Cox model was fitted, taking RA diagnosis as the starting point. Individual random effects were assumed to be correlated as a function of the corresponding kinship coefficients. The variance of the random effect was 4 10⁻⁴. RA: rheumatoid arthritis; DB: diffuse bronchiectasis.</p

Characteristics and outcome of the 137 participants in the family-based cohort study.

<p>RA: rheumatoid arthritis; DB: diffuse bronchiectasis. <i>CFTR</i>: cystic fibrosis transmembrane conductance regulator gene.</p><p>Plus-minus values are means+SD.</p>a<p> <i>P</i>-values of Fisher exact tests.</p>b<p> <i>P</i>-values of Kruskal-Wallis tests.</p><p>* Causes of death included CVA, Hodgkin lymphoma, cancer, and refractory RA, in one patient each.</p>†<p> Cause of death was CVA.</p>‡<p> Cause of death was cancer.</p>¥<p> Causes of death included cancer in 4 patients and degenerative neurological disease in one patient.</p><p>Characteristics and outcome of the 137 participants in the family-based cohort study.</p